Full-Time

Senior Clinical Trial Manager

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$116k - $145kAnnually

+ Equity Awards

Senior

San Carlos, CA, USA

Hybrid position; requires some in-office days.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BS or MS degree with a minimum of 7 years clinical operations experience in the pharmaceutical or biotech industry, preferably the majority in oncology drug development
  • Hands-on experience of running early-stage clinical trials within an industry environment
  • Strong working knowledge of FDA Regulations, ICH Guidelines and GCPs governing the conduct of clinical trials
  • Experience in selection of CROs/ vendors and management of external resources
  • A demonstrable record of strong vendor management and teamwork
  • Direct experience of managing clinical CROs
  • Thrives in a collaborative team setting and is driven by a desire to deploy innovative approaches and technologies in a high-energy environment
  • Excellent written and verbal communication skills
  • Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important
  • Ability to travel (~25%)
Responsibilities
  • Clinical operations functional activities related to the execution of assigned clinical trials based upon department and corporate goals and objectives
  • Management of clinical studies and vendors to ensure studies are completed on time, within budget and in compliance with Standard Operating Procedures (SOPs), FDA regulations and International Council for Harmonization (ICH)/ GCP guidelines
  • Identify, engage, and manage the activities of clinical CROs and other clinical study providers (e.g., core labs, Electronic Data Capture (EDC) provider, and independent contractors) to execute clinical trials
  • Reviewing and contributing to the development of study-specific documentation including clinical trial protocols, case report forms, study guides/manuals, informed consent forms and clinical database
  • Reviewing monitoring reports and other study documentation as required
  • Oversight of the collection and management of clinical trial documentation to be filed in the Trial Master File (TMF)
  • Participation in team meetings and collaborate with other functional groups within the company (e.g., Clinical Development, Pharmacokinetics, Quantitative Sciences, Regulatory, QA, Finance, Legal, etc.) to achieve clinical study goals
  • Following up on assigned team action items and identification, escalation, and resolution of issues as needed
  • Collaboration with contracts specialist to review and negotiate Clinical Trial Agreements and site specific study budgets
  • Assessment of adequacy/feasibility of potential clinical investigators and sites including evaluating facilities, personnel, patient referral base, and adherence to GCP
  • Development of clinical study monitoring priorities and Monitoring Plan in conjunction with CRO
  • Conduct site visits (e.g., training visits, site initiation visits, monitoring visits), as required
  • Managing investigational product accountability and reconciliation process
  • Assistance with the preparation of safety, interim and final clinical study reports, and resolution of data discrepancies
  • Providing clinical trial support, mentoring, leadership, guidance, and direction to Clinical Research Associates (CRAs) assigned to clinical studies
  • Preparation and tracking of study participant enrollment projections vs. actuals and study budgets
  • Serving as primary clinical operations contact for internal and external (clinical sites, vendors, etc.) teams for assigned studies
Desired Qualifications
  • Experience in working with cooperative group studies and investigator sponsored trials, preferred
  • Experience of Global clinical trial operations outside the USA
  • Excellent knowledge of the APAC region

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to inhibit the activity of RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

11%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.